1 Introduction to Research & Analysis Reports
1.1 Hepatoma Cell Targeted Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Hepatoma Cell Targeted Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Hepatoma Cell Targeted Drug Overall Market Size
2.1 Global Hepatoma Cell Targeted Drug Market Size: 2022 VS 2029
2.2 Global Hepatoma Cell Targeted Drug Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Hepatoma Cell Targeted Drug Players in Global Market
3.2 Top Global Hepatoma Cell Targeted Drug Companies Ranked by Revenue
3.3 Global Hepatoma Cell Targeted Drug Revenue by Companies
3.4 Top 3 and Top 5 Hepatoma Cell Targeted Drug Companies in Global Market, by Revenue in 2022
3.5 Global Companies Hepatoma Cell Targeted Drug Product Type
3.6 Tier 1, Tier 2 and Tier 3 Hepatoma Cell Targeted Drug Players in Global Market
3.6.1 List of Global Tier 1 Hepatoma Cell Targeted Drug Companies
3.6.2 List of Global Tier 2 and Tier 3 Hepatoma Cell Targeted Drug Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Hepatoma Cell Targeted Drug Market Size Markets, 2022 & 2029
4.1.2 Sorafenib
4.1.3 Lenvatinib
4.1.4 Regorafenib
4.1.5 Other
4.2 By Type – Global Hepatoma Cell Targeted Drug Revenue & Forecasts
4.2.1 By Type – Global Hepatoma Cell Targeted Drug Revenue, 2018-2023
4.2.2 By Type – Global Hepatoma Cell Targeted Drug Revenue, 2024-2029
4.2.3 By Type – Global Hepatoma Cell Targeted Drug Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Hepatoma Cell Targeted Drug Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Retail Pharmacy
5.1.4 Other
5.2 By Application – Global Hepatoma Cell Targeted Drug Revenue & Forecasts
5.2.1 By Application – Global Hepatoma Cell Targeted Drug Revenue, 2018-2023
5.2.2 By Application – Global Hepatoma Cell Targeted Drug Revenue, 2024-2029
5.2.3 By Application – Global Hepatoma Cell Targeted Drug Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Hepatoma Cell Targeted Drug Market Size, 2022 & 2029
6.2 By Region – Global Hepatoma Cell Targeted Drug Revenue & Forecasts
6.2.1 By Region – Global Hepatoma Cell Targeted Drug Revenue, 2018-2023
6.2.2 By Region – Global Hepatoma Cell Targeted Drug Revenue, 2024-2029
6.2.3 By Region – Global Hepatoma Cell Targeted Drug Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Hepatoma Cell Targeted Drug Revenue, 2018-2029
6.3.2 US Hepatoma Cell Targeted Drug Market Size, 2018-2029
6.3.3 Canada Hepatoma Cell Targeted Drug Market Size, 2018-2029
6.3.4 Mexico Hepatoma Cell Targeted Drug Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Hepatoma Cell Targeted Drug Revenue, 2018-2029
6.4.2 Germany Hepatoma Cell Targeted Drug Market Size, 2018-2029
6.4.3 France Hepatoma Cell Targeted Drug Market Size, 2018-2029
6.4.4 U.K. Hepatoma Cell Targeted Drug Market Size, 2018-2029
6.4.5 Italy Hepatoma Cell Targeted Drug Market Size, 2018-2029
6.4.6 Russia Hepatoma Cell Targeted Drug Market Size, 2018-2029
6.4.7 Nordic Countries Hepatoma Cell Targeted Drug Market Size, 2018-2029
6.4.8 Benelux Hepatoma Cell Targeted Drug Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Hepatoma Cell Targeted Drug Revenue, 2018-2029
6.5.2 China Hepatoma Cell Targeted Drug Market Size, 2018-2029
6.5.3 Japan Hepatoma Cell Targeted Drug Market Size, 2018-2029
6.5.4 South Korea Hepatoma Cell Targeted Drug Market Size, 2018-2029
6.5.5 Southeast Asia Hepatoma Cell Targeted Drug Market Size, 2018-2029
6.5.6 India Hepatoma Cell Targeted Drug Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Hepatoma Cell Targeted Drug Revenue, 2018-2029
6.6.2 Brazil Hepatoma Cell Targeted Drug Market Size, 2018-2029
6.6.3 Argentina Hepatoma Cell Targeted Drug Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Hepatoma Cell Targeted Drug Revenue, 2018-2029
6.7.2 Turkey Hepatoma Cell Targeted Drug Market Size, 2018-2029
6.7.3 Israel Hepatoma Cell Targeted Drug Market Size, 2018-2029
6.7.4 Saudi Arabia Hepatoma Cell Targeted Drug Market Size, 2018-2029
6.7.5 UAE Hepatoma Cell Targeted Drug Market Size, 2018-2029
7 Hepatoma Cell Targeted Drug Companies Profiles
7.1 Bayer
7.1.1 Bayer Company Summary
7.1.2 Bayer Business Overview
7.1.3 Bayer Hepatoma Cell Targeted Drug Major Product Offerings
7.1.4 Bayer Hepatoma Cell Targeted Drug Revenue in Global Market (2018-2023)
7.1.5 Bayer Key News & Latest Developments
7.2 Eisai
7.2.1 Eisai Company Summary
7.2.2 Eisai Business Overview
7.2.3 Eisai Hepatoma Cell Targeted Drug Major Product Offerings
7.2.4 Eisai Hepatoma Cell Targeted Drug Revenue in Global Market (2018-2023)
7.2.5 Eisai Key News & Latest Developments
7.3 Zelgen
7.3.1 Zelgen Company Summary
7.3.2 Zelgen Business Overview
7.3.3 Zelgen Hepatoma Cell Targeted Drug Major Product Offerings
7.3.4 Zelgen Hepatoma Cell Targeted Drug Revenue in Global Market (2018-2023)
7.3.5 Zelgen Key News & Latest Developments
7.4 Cipla
7.4.1 Cipla Company Summary
7.4.2 Cipla Business Overview
7.4.3 Cipla Hepatoma Cell Targeted Drug Major Product Offerings
7.4.4 Cipla Hepatoma Cell Targeted Drug Revenue in Global Market (2018-2023)
7.4.5 Cipla Key News & Latest Developments
7.5 Natco Pharma
7.5.1 Natco Pharma Company Summary
7.5.2 Natco Pharma Business Overview
7.5.3 Natco Pharma Hepatoma Cell Targeted Drug Major Product Offerings
7.5.4 Natco Pharma Hepatoma Cell Targeted Drug Revenue in Global Market (2018-2023)
7.5.5 Natco Pharma Key News & Latest Developments
7.6 BEACON Pharma
7.6.1 BEACON Pharma Company Summary
7.6.2 BEACON Pharma Business Overview
7.6.3 BEACON Pharma Hepatoma Cell Targeted Drug Major Product Offerings
7.6.4 BEACON Pharma Hepatoma Cell Targeted Drug Revenue in Global Market (2018-2023)
7.6.5 BEACON Pharma Key News & Latest Developments
7.7 Jiangxi Shanxiang
7.7.1 Jiangxi Shanxiang Company Summary
7.7.2 Jiangxi Shanxiang Business Overview
7.7.3 Jiangxi Shanxiang Hepatoma Cell Targeted Drug Major Product Offerings
7.7.4 Jiangxi Shanxiang Hepatoma Cell Targeted Drug Revenue in Global Market (2018-2023)
7.7.5 Jiangxi Shanxiang Key News & Latest Developments
7.8 Yao Pharma
7.8.1 Yao Pharma Company Summary
7.8.2 Yao Pharma Business Overview
7.8.3 Yao Pharma Hepatoma Cell Targeted Drug Major Product Offerings
7.8.4 Yao Pharma Hepatoma Cell Targeted Drug Revenue in Global Market (2018-2023)
7.8.5 Yao Pharma Key News & Latest Developments
7.9 CSPC
7.9.1 CSPC Company Summary
7.9.2 CSPC Business Overview
7.9.3 CSPC Hepatoma Cell Targeted Drug Major Product Offerings
7.9.4 CSPC Hepatoma Cell Targeted Drug Revenue in Global Market (2018-2023)
7.9.5 CSPC Key News & Latest Developments
7.10 CHIATAI Tianqing
7.10.1 CHIATAI Tianqing Company Summary
7.10.2 CHIATAI Tianqing Business Overview
7.10.3 CHIATAI Tianqing Hepatoma Cell Targeted Drug Major Product Offerings
7.10.4 CHIATAI Tianqing Hepatoma Cell Targeted Drug Revenue in Global Market (2018-2023)
7.10.5 CHIATAI Tianqing Key News & Latest Developments
7.11 Simcere
7.11.1 Simcere Company Summary
7.11.2 Simcere Business Overview
7.11.3 Simcere Hepatoma Cell Targeted Drug Major Product Offerings
7.11.4 Simcere Hepatoma Cell Targeted Drug Revenue in Global Market (2018-2023)
7.11.5 Simcere Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
世界の肝癌細胞用標的治療薬市場予測2023-2029：ソラフェニブ、レンバチニブ、レゴラフェニブ、その他 |
| 【英語タイトル】Hepatoma Cell Targeted Drug Market, Global Outlook and Forecast 2023-2029 | |
 | ・商品コード：MMG23JU5613 ・発行会社（調査会社）：Market Monitor Global ・発行日：2023年6月 ・ページ数：67 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール（受注後2-3営業日） ・調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど ・産業分野：医薬品＆医療 |
| Single User（1名様閲覧用） | USD3,250 ⇒換算￥494,000 | 見積依頼/購入/質問フォーム |
| Multi User（20名様閲覧用） | USD4,225 ⇒換算￥642,200 | 見積依頼/購入/質問フォーム |
| Enterprise User（閲覧人数制限なし） | USD4,875 ⇒換算￥741,000 | 見積依頼/購入/質問フォーム |
|
※販売価格オプションの説明 ※お支払金額：換算金額（日本円）＋消費税 ※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡） ※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能） |
| 当調査レポートは次の情報を含め、世界の肝癌細胞用標的治療薬市場規模と予測を収録しています。・世界の肝癌細胞用標的治療薬市場：売上、2018年-2023年、2024年-2029年 ・世界の肝癌細胞用標的治療薬市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の肝癌細胞用標的治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「ソラフェニブ」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 肝癌細胞用標的治療薬のグローバル主要企業は、Bayer、 Eisai、 Zelgen、 Cipla、 Natco Pharma、 BEACON Pharma、 Jiangxi Shanxiang、 Yao Pharma、 CSPC、 CHIATAI Tianqing、 Simcereなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、肝癌細胞用標的治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の肝癌細胞用標的治療薬市場：タイプ別、2018年-2023年、2024年-2029年 世界の肝癌細胞用標的治療薬市場：タイプ別市場シェア、2022年 ・ソラフェニブ、レンバチニブ、レゴラフェニブ、その他 世界の肝癌細胞用標的治療薬市場：用途別、2018年-2023年、2024年-2029年 世界の肝癌細胞用標的治療薬市場：用途別市場シェア、2022年 ・病院、小売薬局、その他 世界の肝癌細胞用標的治療薬市場：地域・国別、2018年-2023年、2024年-2029年 世界の肝癌細胞用標的治療薬市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における肝癌細胞用標的治療薬のグローバル売上、2018年-2023年 ・主要企業における肝癌細胞用標的治療薬のグローバル売上シェア、2022年 ・主要企業における肝癌細胞用標的治療薬のグローバル販売量、2018年-2023年 ・主要企業における肝癌細胞用標的治療薬のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Bayer、 Eisai、 Zelgen、 Cipla、 Natco Pharma、 BEACON Pharma、 Jiangxi Shanxiang、 Yao Pharma、 CSPC、 CHIATAI Tianqing、 Simcere ************************************************************* ・調査・分析レポートの概要 肝癌細胞用標的治療薬市場の定義 市場セグメント 世界の肝癌細胞用標的治療薬市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の肝癌細胞用標的治療薬市場規模 世界の肝癌細胞用標的治療薬市場規模：2022年 VS 2029年 世界の肝癌細胞用標的治療薬市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの肝癌細胞用標的治療薬の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の肝癌細胞用標的治療薬製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：ソラフェニブ、レンバチニブ、レゴラフェニブ、その他 肝癌細胞用標的治療薬のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：病院、小売薬局、その他 肝癌細胞用標的治療薬の用途別グローバル売上・予測 ・地域別市場分析 地域別肝癌細胞用標的治療薬市場規模 2022年と2029年 地域別肝癌細胞用標的治療薬売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Bayer、 Eisai、 Zelgen、 Cipla、 Natco Pharma、 BEACON Pharma、 Jiangxi Shanxiang、 Yao Pharma、 CSPC、 CHIATAI Tianqing、 Simcere ... |
The most effective targeted drug introduced for HCC has been sorafenib. Sorafenib, a multi-tyrosine kinase inhibitor (TKI), remains the only systemic targeted tumor therapy in use for advanced HCC (18-21).
This report aims to provide a comprehensive presentation of the global market for Hepatoma Cell Targeted Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hepatoma Cell Targeted Drug. This report contains market size and forecasts of Hepatoma Cell Targeted Drug in global, including the following market information:
Global Hepatoma Cell Targeted Drug Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Hepatoma Cell Targeted Drug market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Sorafenib Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Hepatoma Cell Targeted Drug include Bayer, Eisai, Zelgen, Cipla, Natco Pharma, BEACON Pharma, Jiangxi Shanxiang, Yao Pharma and CSPC, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Hepatoma Cell Targeted Drug companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hepatoma Cell Targeted Drug Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Hepatoma Cell Targeted Drug Market Segment Percentages, by Type, 2022 (%)
Sorafenib
Lenvatinib
Regorafenib
Other
Global Hepatoma Cell Targeted Drug Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Hepatoma Cell Targeted Drug Market Segment Percentages, by Application, 2022 (%)
Hospital
Retail Pharmacy
Other
Global Hepatoma Cell Targeted Drug Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Hepatoma Cell Targeted Drug Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hepatoma Cell Targeted Drug revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Hepatoma Cell Targeted Drug revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bayer
Eisai
Zelgen
Cipla
Natco Pharma
BEACON Pharma
Jiangxi Shanxiang
Yao Pharma
CSPC
CHIATAI Tianqing
Simcere
Outline of Major Chapters:
Chapter 1: Introduces the definition of Hepatoma Cell Targeted Drug, market overview.
Chapter 2: Global Hepatoma Cell Targeted Drug market size in revenue.
Chapter 3: Detailed analysis of Hepatoma Cell Targeted Drug company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Hepatoma Cell Targeted Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
❖ レポートの目次 ❖
| ★調査レポート[世界の肝癌細胞用標的治療薬市場予測2023-2029：ソラフェニブ、レンバチニブ、レゴラフェニブ、その他] (コード：MMG23JU5613)販売に関する免責事項を必ずご確認ください。 |
| ★調査レポート[世界の肝癌細胞用標的治療薬市場予測2023-2029：ソラフェニブ、レンバチニブ、レゴラフェニブ、その他]についてメールでお問い合わせ |
